Last reviewed · How we verify
Glycopyrrolate 0.2 MG
At a glance
| Generic name | Glycopyrrolate 0.2 MG |
|---|---|
| Also known as | Glycopyrronium Injection |
| Sponsor | Tanta University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Foul, salty or metallic taste
- Nausea or Vomiting
- Headache
- nausea or vomiting
- Itching
- Cough
- Foul, salty, or metallic taste
- Bronchospasm
Key clinical trials
- Sugammadex-Induced Clenching During Neuromuscular Blockade Reversal (NA)
- Sugammadex To IMprove Bowel Function (PHASE4)
- The Effect of Deep Block Versus Moderate Block on the Stress Response After Laparoscopic Gastrectomy (PHASE4)
- Antiperistaltic Effect and Safety of Glycopyrronium for Colonoscopic Polypectomy (PHASE1, PHASE2)
- Neuromuscular Blockade in Patients With Severe Renal Impairment (PHASE2)
- Memory Changes in Patients With Major Depression Disorder Treated With ECT (NA)
- Dexmedetomine as Adjuvant for Spinal Anesthesia in Elective Cesarian Sections : a Pilot Study (PHASE3)
- Effect of Glycopyrrolate on Vasopressors Requirement for Non-elective Caesarean Section Under Spinal Anaesthesia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glycopyrrolate 0.2 MG CI brief — competitive landscape report
- Glycopyrrolate 0.2 MG updates RSS · CI watch RSS
- Tanta University portfolio CI